ONFI Drug Patent Profile
✉ Email this page to a colleague
When do Onfi patents expire, and what generic alternatives are available?
Onfi is a drug marketed by Lundbeck Pharms Llc and is included in two NDAs.
The generic ingredient in ONFI is clobazam. There are ten drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the clobazam profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Onfi
A generic version of ONFI was approved as clobazam by AMNEAL on October 22nd, 2018.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for ONFI?
- What are the global sales for ONFI?
- What is Average Wholesale Price for ONFI?
Summary for ONFI
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 2 |
| Finished Product Suppliers / Packagers: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 37 |
| Patent Applications: | 3,812 |
| Drug Prices: | Drug price information for ONFI |
| What excipients (inactive ingredients) are in ONFI? | ONFI excipients list |
| DailyMed Link: | ONFI at DailyMed |
Pharmacology for ONFI
| Drug Class | Benzodiazepine |
| Mechanism of Action | Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A4 Inducers |
US Patents and Regulatory Information for ONFI
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lundbeck Pharms Llc | ONFI | clobazam | SUSPENSION;ORAL | 203993-001 | Dec 14, 2012 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Lundbeck Pharms Llc | ONFI | clobazam | TABLET;ORAL | 202067-003 | Oct 21, 2011 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Lundbeck Pharms Llc | ONFI | clobazam | TABLET;ORAL | 202067-001 | Oct 21, 2011 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Lundbeck Pharms Llc | ONFI | clobazam | TABLET;ORAL | 202067-002 | Oct 21, 2011 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
